查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1166122

抗凝固拮抗劑的全球市場:成長，未來預測，競爭分析(2022年～2030年)

Anticoagulant Reversal Drugs Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030
出版日期: | 出版商: Acute Market Reports | 英文 120 Pages | 商品交期: 最快1-2個工作天內

價格

全球抗凝固拮抗劑的市場規模，在2022年～2030年之間的預測期間內預計以15.3％的年複合成長率成長。

本報告提供全球抗凝固拮抗劑市場相關調查分析，市場趨勢，市場動態，各市場區隔、各地區的市場分析，競爭情形，企業簡介等系統性資訊。

目錄

第1章 序文

  • 報告的說明
    • 報告的目的
    • 目標受眾
    • 主要的產品
  • 市場明細
  • 調查手法
    • I期:2次調查
    • II期:1次調查
    • III期:各專家審查
    • 前提條件
    • 所採用的方法

第2章 摘要整理

  • 市場概述:全球抗凝固拮抗劑市場
  • 全球抗凝固拮抗劑市場(2021年)
  • 全球抗凝固拮抗劑市場:各類藥物(2021年)
  • 全球抗凝固拮抗劑市場:各地區(2021年)
  • COVID-19影響
  • 富有魅力的投資提案:各地區(2021年)
  • 競爭分析
    • 主要的抗凝固拮抗劑市場供應商的市場定位
    • 抗凝固拮抗劑市場供應商採用的策略
    • 主要的產業策略

第3章 抗凝固拮抗劑市場:商務的預測與市場動態

  • 簡介
  • 抗凝固拮抗劑的市場價值(2020年～2030年)
  • 市場動態
    • 推動市場要素
    • 阻礙市場要素
    • 主要的課題
    • 主要的機會
  • 促進因素與阻礙因素的影響分析
  • See-Saw分析
  • 波特的五力分析
    • 供給企業談判力
    • 買方議價能力
    • 替代品的威脅
    • 新加入業者的威脅
    • 競爭企業間的敵對關係
  • PESTEL分析
    • 政治形勢
    • 經濟形勢
    • 技術形勢
    • 法律上的形勢
    • 社會形勢

第4章 抗凝固拮抗劑市場(2020年～2030年)

  • 市場概要
  • 成長、收益分析:2021年對2030年
  • 市場明細

第5章 抗凝固拮抗劑市場:各類藥物(2020年～2030年)

  • 市場概要
  • 成長、收益分析:2021年對2030年
  • 市場明細
    • 凝血素原複合體濃縮物(PCC)
    • 維他命K
    • 魚精蛋白
    • 傳明酸
    • 去氨加壓素
    • Idarucizumab
    • Andexxa
    • 開發平台分析
    • Ⅲ期藥(至2026年的預測)
    • Octaplex
    • I、II期的藥物

第6章 北美的抗凝固拮抗劑市場(2020年～2030年)

  • 市場概要
  • 2020年～2030年
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 北美

第7章 英國、EU的抗凝固拮抗劑市場(2020年～2030年)

  • 市場概要
  • 2020年～2030年
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 英國、EU

第8章 亞太地區的抗凝固拮抗劑市場(2020年～2030年)

  • 市場概要
  • 2020年～2030年
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 亞太地區

第9章 南美的抗凝固拮抗劑市場(2020年～2030年)

  • 市場概要
  • 2020年～2030年
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 南美

第10章 中東、非洲的抗凝固拮抗劑市場(2020年～2030年)

  • 市場概要
  • 2020年～2030年
  • 各類藥物(2020年～2030年)
  • 各地區(2020年～2030年)
    • 中東、非洲

第11章 企業簡介

  • Boehringer Ingelheim GmbH
  • Fresenius Kabi AG
  • Pfizer, Inc.
  • Bausch Health Companies, Inc.
  • Amneal Pharmaceuticals, Inc.
  • CSL Behring Limited
  • Octapharma AG
  • Portola Pharmaceuticals, Inc.
  • Perosphere Pharmaceuticals, Inc.
  • Ferring Pharmaceuticals
Product Code: 138615-08-22

Industry Outlook

The global anticoagulant reversal drugs market expected to grow at compound annual growth rate (CAGR) of 15.3% during the forecast period from 2022 to 2030. Reversing the effects of anticoagulants including novel oral anticoagulants (NOACs), Vitamin K antagonist and others is a major concern in clinical practice especially during life-threatening bleeding episodes and emergency surgery. Approvals of NOACs in last decade has increased the usage of these factor Xa inhibitors in preventing and treating various medical conditions such as stroke, pulmonary embolism, atrial fibrillation, and deep vein thrombosis (DVT). However, this growth in anticoagulants usage has led to the rise in the incidence of hospitals admissions and death due to increased bleeding due to anticoagulation. According to Centers for Disease Control and Prevention (CDC), in the year 2016, approximately 117,000 people were hospitalized in U.S. alone and close to 2,000 deaths per month attributable to anticoagulation or factor Xa inhibitor related bleeding. These factors have led to furious research and development of anticoagulant reversal agents. The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) has granted special status and accelerated approvals for development and swift market entry of certain anticoagulant antidotes.

"Recent Approval of First Reversal Agent for Apixaban and Rivaroxaban Anticoagulants Will Drive the Market"

In May 2018, The U.S. FDA approved Andexxa, the first factor Xa inhibitor reversal agent by Portola Pharmaceutical, Inc. The drug can act as an antidote for patients being treated with rivaroxaban (Xarelto) and apixaban (Eliquis) during uncontrolled bleeding and life-threatening situations by reversing of anticoagulation effects. Andexxa received both orphan drug status and breakthrough designation by U.S. FDA and has shown prominent clinical efficiency during clinical trials. Increased use of factor Xa inhibitors will drive the market for Andexxa, helping it to grow at fastest rate during the forecast period. Idarucizumab and Prothrombin Complex Concentrates also hold a significant share in the anticoagulant reversal drugs market owing to increased use of these agents during critical situation. Idarucizumab, approved in 2015 was the only drug for reversing the anticoagulation effects of dabigatran etexilate mesylate.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Anticoagulant Reversal Drugs market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report

Micro and macro environment factors that are currently influencing the Anticoagulant Reversal Drugs market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Segmentation

Drug Class

Prothrombin Complex Concentrates (PCC)

Vitamin K

Protamine

Tranexmic Acid

Desmopressin

Idarucizumab

Andexxa

Pipeline Analysis

Phase III Drugs (Forecast till 2026)

Octaplex

Phase I and II Drugs (Tabular Representation)

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

UK

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of Covid-19 Segment (2020-2021; US$ Million )

Pre Covid-19 situation

Post Covid-19 situation

Key questions answered in this report

What are the key micro and macro environmental factors that are impacting the growth of Anticoagulant Reversal Drugs market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Anticoagulant Reversal Drugs market?

Which is the largest regional market for Anticoagulant Reversal Drugs market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Anticoagulant Reversal Drugs market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Anticoagulant Reversal Drugs market worldwide?

Table of Contents

1. Preface

  • 1.1. Report Description
    • 1.1.1. Purpose of the Report
    • 1.1.2. Target Audience
    • 1.1.3. Key Offerings
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
    • 1.3.1. Phase I - Secondary Research
    • 1.3.2. Phase II - Primary Research
    • 1.3.3. Phase III - Expert Panel Review
    • 1.3.4. Assumptions
    • 1.3.5. Approach Adopted

2. Executive Summary

  • 2.1. Market Snapshot: Global Anticoagulant Reversal Drugs Market
  • 2.2. Global Anticoagulant Reversal Drugs Market, By , 2021 (US$ Million)
  • 2.3. Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021 (US$ Million)
  • 2.4. Global Anticoagulant Reversal Drugs Market, By Geography, 2021 (US$ Million)
  • 2.5. Impact of Covid 19
  • 2.6. Attractive Investment Proposition by Geography, 2021
  • 2.7. Competitive Analysis
    • 2.7.1. Market Positioning of Key Anticoagulant Reversal Drugs Market Vendors
    • 2.7.2. Strategies Adopted by Anticoagulant Reversal Drugs Market Vendors
    • 2.7.3. Key Industry Strategies

3. Anticoagulant Reversal Drugs Market: Business Outlook & Market Dynamics

  • 3.1. Introduction
  • 3.2. Global Anticoagulant Reversal Drugs Market Value, 2020 - 2030, (US$ Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers
    • 3.3.2. Market Restraints
    • 3.3.3. Key Challenges
    • 3.3.4. Key Opportunities
  • 3.4. Impact Analysis of Drivers and Restraints
  • 3.5. See-Saw Analysis
  • 3.6. Porter's Five Force Model
    • 3.6.1. Supplier Power
    • 3.6.2. Buyer Power
    • 3.6.3. Threat Of Substitutes
    • 3.6.4. Threat Of New Entrants
    • 3.6.5. Competitive Rivalry
  • 3.7. PESTEL Analysis
    • 3.7.1. Political Landscape
    • 3.7.2. Economic Landscape
    • 3.7.3. Technology Landscape
    • 3.7.4. Legal Landscape
    • 3.7.5. Social Landscape

4. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)

  • 4.1. Market Overview
  • 4.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 4.3. Market Segmentation

5. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)

  • 5.1. Market Overview
  • 5.2. Growth & Revenue Analysis: 2021 Versus 2030
  • 5.3. Market Segmentation
    • 5.3.1. Prothrombin Complex Concentrates (PCC)
    • 5.3.2. Vitamin K
    • 5.3.3. Protamine
    • 5.3.4. Tranexmic Acid
    • 5.3.5. Desmopressin
    • 5.3.6. Idarucizumab
    • 5.3.7. Andexxa
    • 5.3.8. Pipeline Analysis
    • 5.3.9. Phase III Drugs (Forecast till 2026)
    • 5.3.10. Octaplex
    • 5.3.11. Phase I and II Drugs (Tabular Representation)

6. North America Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 6.1. Market Overview
  • 6.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 6.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 6.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 6.4.1.North America
      • 6.4.1.1. U.S.
      • 6.4.1.2. Canada
      • 6.4.1.3. Rest of North America

7. UK and European Union Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 7.1. Market Overview
  • 7.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 7.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 7.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 7.4.1.UK and European Union
      • 7.4.1.1. UK
      • 7.4.1.2. Germany
      • 7.4.1.3. Spain
      • 7.4.1.4. Italy
      • 7.4.1.5. France
      • 7.4.1.6. Rest of Europe

8. Asia Pacific Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 8.1. Market Overview
  • 8.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 8.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 8.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 8.4.1.Asia Pacific
      • 8.4.1.1. China
      • 8.4.1.2. Japan
      • 8.4.1.3. India
      • 8.4.1.4. Australia
      • 8.4.1.5. South Korea
      • 8.4.1.6. Rest of Asia Pacific

9. Latin America Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 9.1. Market Overview
  • 9.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 9.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 9.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 9.4.1.Latin America
      • 9.4.1.1. Brazil
      • 9.4.1.2. Mexico
      • 9.4.1.3. Rest of Latin America

10. Middle East and Africa Anticoagulant Reversal Drugs Market, 2020-2030, USD (Million)

  • 10.1. Market Overview
  • 10.2. Anticoagulant Reversal Drugs Market: By , 2020-2030, USD (Million)
  • 10.3. Anticoagulant Reversal Drugs Market: By Drug Class , 2020-2030, USD (Million)
  • 10.4.Anticoagulant Reversal Drugs Market: By Region, 2020-2030, USD (Million)
    • 10.4.1.Middle East and Africa
      • 10.4.1.1. GCC
      • 10.4.1.2. Africa
      • 10.4.1.3. Rest of Middle East and Africa

11. Company Profile

  • 11.1. Boehringer Ingelheim GmbH
    • 11.1.1. Company Overview
    • 11.1.2. Financial Performance
    • 11.1.3. Product Portfolio
    • 11.1.4. Strategic Initiatives
  • 11.2. Fresenius Kabi AG
    • 11.2.1. Company Overview
    • 11.2.2. Financial Performance
    • 11.2.3. Product Portfolio
    • 11.2.4. Strategic Initiatives
  • 11.3. Pfizer, Inc.
    • 11.3.1. Company Overview
    • 11.3.2. Financial Performance
    • 11.3.3. Product Portfolio
    • 11.3.4. Strategic Initiatives
  • 11.4. Bausch Health Companies, Inc.
    • 11.4.1. Company Overview
    • 11.4.2. Financial Performance
    • 11.4.3. Product Portfolio
    • 11.4.4. Strategic Initiatives
  • 11.5. Amneal Pharmaceuticals, Inc.
    • 11.5.1. Company Overview
    • 11.5.2. Financial Performance
    • 11.5.3. Product Portfolio
    • 11.5.4. Strategic Initiatives
  • 11.6. CSL Behring Limited
    • 11.6.1. Company Overview
    • 11.6.2. Financial Performance
    • 11.6.3. Product Portfolio
    • 11.6.4. Strategic Initiatives
  • 11.7. Octapharma AG
    • 11.7.1. Company Overview
    • 11.7.2. Financial Performance
    • 11.7.3. Product Portfolio
    • 11.7.4. Strategic Initiatives
  • 11.8. Portola Pharmaceuticals, Inc.
    • 11.8.1. Company Overview
    • 11.8.2. Financial Performance
    • 11.8.3. Product Portfolio
    • 11.8.4. Strategic Initiatives
  • 11.9. Perosphere Pharmaceuticals, Inc.
    • 11.9.1. Company Overview
    • 11.9.2. Financial Performance
    • 11.9.3. Product Portfolio
    • 11.9.4. Strategic Initiatives
  • 11.10. Ferring Pharmaceuticals
    • 11.10.1. Company Overview
    • 11.10.2. Financial Performance
    • 11.10.3. Product Portfolio
    • 11.10.4. Strategic Initiatives

List of Tables

  • TABLE 1 Global Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 2 Global Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 3 North America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 4 North America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 5 UK and European Union Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 6 UK and European Union Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 7 Asia Pacific Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 8 Asia Pacific Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 9 Latin America Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 10 Latin America Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)
  • TABLE 11 Middle East and Africa Anticoagulant Reversal Drugs Market By , 2020-2030, USD (Million)
  • TABLE 12 Middle East and Africa Anticoagulant Reversal Drugs Market By Drug Class , 2020-2030, USD (Million)

List of Figures

  • FIG. 1 Global Anticoagulant Reversal Drugs Market: Market Coverage
  • FIG. 2 Research Methodology and Data Sources
  • FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
  • FIG. 4 Global Anticoagulant Reversal Drugs Market: Quality Assurance
  • FIG. 5 Global Anticoagulant Reversal Drugs Market, By , 2021
  • FIG. 6 Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021
  • FIG. 7 Global Anticoagulant Reversal Drugs Market, By Geography, 2021
  • FIG. 8 Global Anticoagulant Reversal Drugs Market, By , 2021 Vs 2030, %
  • FIG. 9 Global Anticoagulant Reversal Drugs Market, By Drug Class , 2021 Vs 2030, %
  • FIG. 10 U.S. Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 11 Canada Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 12 Rest of North America Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 13 UK Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 14 Germany Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 15 Spain Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 16 Italy Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 17 France Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 18 Rest of Europe Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 19 China Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 20 Japan Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 21 India Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 22 Australia Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 23 South Korea Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 24 Rest of Asia Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 25 Brazil Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 26 Mexico Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 27 Rest of Latin America Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 28 GCC Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 29 Africa Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030
  • FIG. 30 Rest of Middle East and Africa Anticoagulant Reversal Drugs Market (US$ Million), 2020 - 2030